Health Canada has expanded the labelling flexibility available to natural health products (NHPs) and certain non-prescription drugs through an updated List of Interchangeable Terms.
Announced in Natural Health Product Licensing Bulletin No. 12 on August 20, 2026, the update allows companies to use clearer or more consumer-friendly language without necessarily changing the meaning authorized by Health Canada.
The List of Interchangeable Terms identifies words and phrases that may be substituted on product labels when alternative wording conveys the same meaning as the authorized term.
Examples include:
Following stakeholder feedback, Health Canada has broadened the application of this policy in three important ways.
First, interchangeable terms may now be used within NHP uses or indications, commonly referred to as product claims. This provides licence holders with greater flexibility to present authorized claims in language that consumers can more readily understand.
Second, the same flexible approach now applies to certain low-risk non-prescription drugs included on List D, provided the products follow the applicable Health Canada monographs. These product categories include sunscreens, acne treatments, anti-dandruff products, antiperspirants, mouthwashes, and medicated skin care products.
Third, Health Canada has clarified that the table contains examples rather than an exhaustive list for NHPs and List D non-prescription drugs. Other terms may therefore be acceptable when they convey the same meaning and comply with the requirements of the guidance.
The update can help NHP companies create labels that are easier for consumers to read while remaining aligned with the product’s terms of market authorization. In most cases, using an acceptable interchangeable term on an NHP label does not require a notification or post-licence amendment.
However, the policy does not authorize companies to expand, strengthen, or otherwise change an approved claim. Every substitution must preserve the meaning of the authorized wording and must not create a false, misleading, or deceptive impression.
Context remains critical. A term that is acceptable in one statement may alter the meaning or regulatory significance of another. Product Facts Table (PFT) headings and subheadings also remain subject to specific limitations.
For non-prescription drugs outside List D, the table continues to operate as an exhaustive list, and interchangeable terms cannot be applied to authorized claims.
Greater flexibility also requires careful regulatory judgement. Source Nutraceutical, Inc. (SNI) supports NHP and non-prescription drug companies with Canadian label reviews, claim assessments, PFT development, licence amendments and market-entry strategy.
Our team can assess whether proposed consumer-friendly wording remains consistent with the product’s authorization and broader Canadian labelling requirements, helping companies improve label clarity without introducing avoidable compliance risk.
Contact SNI to discuss your Canadian NHP or non-prescription drug labelling project.
Effective June 2, 2026, Health Canada will classify melatonin products sold for sleep-related use in children and adolescents under 18 years of age as prescription drugs under the Food and Drug Regulations. Adult-use melatonin natural health products (NHPs) are not affected, provided they remain authorized and positioned for adult use only.
Health Canada is planning a more flexible approach to NHP labelling in Canada, with draft amendments to the Natural Health Products Regulations expected in spring 2027. This article explains what the updated proposal may mean for Product Facts Table flexibility, digital labelling, medicinal ingredient presentation, small package guidance, and the June 2028 transition timeline.
The content on this website, including information presented in this post, is provided for general informational purposes only and does not constitute legal, regulatory, or professional advice. While efforts are made to ensure accuracy, laws and regulations vary by jurisdiction and may change over time. Readers should not rely on this information as a substitute for advice from qualified legal or regulatory professionals. We disclaim any liability for actions taken based on this content, and users are encouraged to seek guidance specific to their circumstances.
